Member Info for Yorkshirepragma

Illustrative of support for ‘tumour targeting ‘. Of mote interest will be which Pharma major is ‘ reviewing with AS’. Time to put ear to ground!

GLA

The tone of the Q& A was so upbeat, when deals mentioned ,it was clearly the case imho…

Gla

I’ll bet my Harrogate mortgage on it there will be deals already being discussed / tentatively agreed. Pharma is a HIGHLY collegiate business…

3-6 m ..

GLA

DTW.. couldn’t agree more.,relevance for me is the move even at commencement of 2. My take is as soon as it’s “sure” it’s a go.

As the likes of Takeda etc , are working closely alongside Av. then we may see a bid/deal / other.

Gla

Apologies…erratum

One drug just into 2

Remainder phase 1 or in dev.

..similar?

…in phase 1 ….$2.4bn….

https://www.biopharmadive.com/news/eli-lilly-dice-deal-acquisition-oral-autoimmune-il-17/653332/

…extraordinary chemistry.

… q&a commentary from team +++

…pharma always seeking opportunity

….ceo./chair reflecting on ‘deals to be done’

…limited opportunity on this scale for global pharma.

… pharma deals done at this stage for good level.

..no brainier…

Hold

The significance of the CEO/ Chairs comments cannot be underestimated as a sign on the positive way forward here.

Have a listen!

‘Commercialisation and licensing etc “…

GLA

Hope not…poorer tech

Already talking….

TIFM

The significance of the CEO/ Chairs comments cannot be underestimated as a sign on the positive way forward here.

Have a listen!

GLA ( no longer needed )

For a scientist of AS calibre , that’s definitely a yes .

There are significant interested parties. This tech is hipot.

Gla

With significant interest out there ,as a ‘unique scientific ‘ offering Aff,tech will have a great future…

Notable point that M& A perceived to be picking up.

In the collegiate world of pharma, there will be significant interest here already.

The previous M& A experience is that early stage research companies can make $1.5 bn, and with greater scope ( read affimers / atypical proving profile ( Dox.),this fig can move up.

At later stage worlds your oyster..

…..

Https://www.dicetherapeutics.com/pipeline/

Just out the blocks tooo…

Https://www.biopharmadive.com/news/eli-lilly-dice-deal-acquisition-oral-autoimmune-il-17/653332/

Eli Lilly squires Dice for $2.4bn.. autoimmune developer.

GLA as if it’s now mreded

In as much this board has value as a source ..the BPharma sector will not need attracting to this framework opportunity.

GLA

NB. This news is certainly all the clarification Pharma needs vis pot. M&A.

GLA

On the ‘balance of probabilities’ ,there is now a high likelihood that the co will ‘seek interest’ in a positive set of alliances to strengthen the co.

It has the potential from the extraordinary depth of the Affimer platform to be successful.

In the close science biotech ,pharms community this has attracted sig. interest.

GLA

V-S, the most astute point made today…and his task will be to court bids GF.

On y va..

GLA